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Despite reducing progression and promoting regression of coronary atherosclerosis, statin ther-
apy does not fully address residual cardiovascular (CV) risk. High-purity eicosapentaenoic acid
(EPA) added to a statin has been shown to reduce CV events and induce regression of coronary
atherosclerosis in imaging studies; however, data are from Japanese populations without high
triglyceride (TG) levels and baseline EPA serum levels greater than those in North American
populations. Icosapent ethyl is a high-purity prescription EPA ethyl ester approved at 4 g/d as
an adjunct to diet to reduce TG levels in adults with TG levels >499 mg/dL. The objective of
the randomized, double-blind, placebo-controlled EVAPORATE study is to evaluate the effects
of icosapent ethyl 4 g/d on atherosclerotic plaque in a North American population of statin-
treated patients with coronary atherosclerosis, TG levels of 200 to 499 mg/dL, and low-density
lipoprotein cholesterol levels of 40 to 115 mg/dL. The primary endpoint is change in low-
attenuation plaque volume measured by multidetector computed tomography angiography.
Secondary endpoints include incident plaque rates; quantitative changes in different plaque
types and morphology; changes in markers of inflammation, lipids, and lipoproteins; and the
relationship between these changes and plaque burden and/or plaque vulnerability. Approxi-
mately 80 patients will be followed for 9 to 18 months. The clinical implications of icosapent
ethyl 4 g/d treatment added to statin therapy on CV endpoints are being evaluated in the large
CV outcomes study REDUCE-IT. EVAPORATE will provide important imaging-derived data that
may add relevance to the clinically derived outcomes from REDUCE-IT.
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1 | INTRODUCTION
Statin therapy is the cornerstone of cardiovascular (CV) risk manage-
ment. Despite reducing the progression of coronary atherosclerosis
and promoting its regression, statin therapy does not fully address
residual CV risk.1 This underscores the need for additional intervention.
Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty
acid that is incorporated into membrane phospholipids and athero-
sclerotic plaques. EPA exerts beneficial effects on the pathophysio-
logic cascade of plaque development, beginning from the onset of
plaque formation through plaque rupture (Figure 1).2,3 A number of
specific salutary actions have been reported relating to endothelial
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function, oxidative stress, foam-cell formation, inflammation, plaque
formation/progression, platelet aggregation, thrombus formation, and
plaque rupture (Figure 1).2 EPA-enriched high-density lipoprotein
(HDL) particles, from patients with dyslipidemia treated with 1.8 g of
EPA and in reconstituted HDL particles, have been shown to increase
cholesterol efflux from macrophages and markedly inhibit cytokine-
induced expression of adhesion molecules in human umbilical-vein
endothelial cells.4,5 EPA also improves atherogenic dyslipidemia by
reducing triglyceride (TG) levels and remnant cholesterol without rais-
ing low-density lipoprotein cholesterol (LDL-C) levels in patients with
very high TG levels6 and in statin-treated patients with high TG levels
and high residual CV risk.7 High-purity EPA has been shown to
induce beneficial effects on and regression of atherosclerotic plaque
in preclinical studies utilizing animal models of atherosclerosis as well
as in a range of clinical imaging studies, some of which included
statin-treated patients.8 In the Japan EPA Lipid Intervention Study
(JELIS) of >18 000 statin-treated Japanese patients with hypercholes-
terolemia, 1.8 g/d of high-purity EPA significantly reduced the rela-
tive risk of major coronary events by 19% (P = 0.011) compared with
placebo.9 Together, the multifaceted data from mechanistic, patho-
physiologic, outcomes, and plaque-imaging studies support the bio-
logic plausibility of EPA as an antiatherosclerotic agent.2,8 However,
much of the outcomes and plaque-imaging data are from Japanese
populations without high TG levels, and in whom baseline EPA serum
levels are greater than those of Western or North American
populations.
Icosapent ethyl (Vascepa; Amarin Pharma Inc., Bedminster, NJ) is
a high-purity prescription EPA ethyl ester approved by the US Food
and Drug Administration at a dose of 4 g/d as an adjunct to diet for
the reduction of TG levels in adults with TG levels ≥500 mg/dL.10
Icosapent ethyl 4 g/d has been shown to increase serum EPA levels
in a Western population to levels similar to those observed in the
Japanese population from JELIS.11 Icosapent ethyl 4 g/d has also
been shown to reduce the levels of TG and other atherogenic and
inflammatory parameters without raising LDL-C levels, as compared
with placebo, in patients with very high TG levels and in statin-
treated patients with high TG levels and high CV risk.6,7,12–14 It is
unknown whether adding icosapent ethyl to a statin will further
reduce the progression of coronary atherosclerosis in Western/North
American populations with residually high TG levels.
The objective of the Effect of Vascepa on Improving Coronary
Atherosclerosis in People With High Triglycerides Taking Statin Ther-
apy (EVAPORATE; NCT02926027) study is to evaluate the effects of
icosapent ethyl 4 g/d on low-attenuation plaque volume via multide-
tector computed tomography angiography (MDCTA) in a North
American population of statin-treated patients with elevated TG
levels (200–499 mg/dL). We hypothesized that icosapent ethyl 4 g/d
in combination with statin therapy would reduce the progression of
FIGURE 1 The potential effects of EPA on atherosclerosis. Atherosclerosis is a multistep process ranging from endothelial dysfunction to
plaque development, progression, and rupture, leading to thrombus formation and cardiovascular events.2,3 EPA has been reported to have
beneficial effects on multiple atherosclerosis processes including endothelial function, oxidative stress, foam-cell formation, inflammation/
cytokines, plaque formation/progression, platelet aggregation, thrombus formation, and plaque rupture.2 Abbreviations: CE, cholesteryl ester;
EPA, eicosapentaenoic acid; HDL, high-density lipoprotein; IFN, interferon; IL, interleukin; LDL, low-density lipoprotein; MMP, matrix
metalloproteinase; ox-LDL, oxidized low-density lipoprotein; SMC, smooth muscle cell; TG, triglycerides
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low-attenuation plaque volume over 9 to 18 months compared with
the use of statin therapy alone.
2 | METHODS
2.1 | Study design
EVAPORATE is a randomized, double-blind, placebo-controlled trial
being conducted at 2 centers in the United States. Eligible patients
will be randomly assigned to icosapent ethyl 4 g/d or placebo (light
liquid paraffin, matched for color, size, shape, weight, and odor) in a
1:1 fashion. Patients will be followed for ≥9 months or up to
18 months (if efficacy is not achieved at 9 months).
At baseline, patients will undergo a physical examination and an
evaluation of blood pressure, height, weight, and laboratory blood
testing. Cardiac computed tomography angiography (CCTA), using
state-of-the-art MDCTA technology, will be used to evaluate coro-
nary plaque volume/composition (for additional details see Support-
ing Information, Appendix, in the online version of this article). The
evaluations of plaque using CCTA will be repeated at month 9 and, if
needed, at month 18. Adverse events will be monitored throughout
the study. The trial schema is shown in Figure 2.
2.2 | Study population
Major study inclusion and exclusion criteria are summarized in
Table 1. Briefly, eligible patients will be age 30 to 85 years with coro-
nary atherosclerosis (narrowing of ≥20% in 1 coronary artery by
either invasive angiography or MDCTA) and elevated fasting TG
levels (200–499 mg/dL) and LDL-C levels ≥40 and ≤115 mg/dL.
Statin therapy (with or without ezetimibe) as well as diet and exercise
must be stable for ≥4 weeks prior to study entry.
2.3 | Study endpoints
The primary endpoint is the rate of change in low-attenuation plaque
volume (defined as −50 to 50 Hounsfield units [HU]; see Supporting
Information, Appendix, in the online version of this article for details)
from baseline to final assessment as measured by MDCTA. Secondary
endpoints are shown in Table 2. These cutoff values were initially
based on Brodoefel and empirically optimized using 3 representative
training sets.
2.4 | Statistical design and analysis
Assuming 80% power and an α of 0.05, a total of 70 patients (35 per
arm) are needed to evaluate the primary outcome of the study (East,
version 6.3; Cytel, Cambridge, MA). Assuming a 15% dropout rate, a
total of 80 (40 per arm) patients are to be enrolled. The initial study
sample size was estimated based on MDCTA data showing
24%  13% reduction in coronary artery plaque volume with
moderate-dose statin therapy.15 It is assumed that an 8% reduction
in plaque volume (one-third that seen with statin therapy) would be
the minimally important change in noncalcified plaque volume based
on past data; multiple studies have shown similar progression/regres-
sion rates with different therapies.16–19 Further data have been
obtained using low-attenuation plaque volume in both MDCTA and
intravascular ultrasound (IVUS) studies. In an integrated backscatter
IVUS (IB-IVUS) study by Niki et al., a statistically significant lipid
FIGURE 2 EVAPORATE study design. At baseline and 9 months, assessments will include BP, height, weight, laboratory blood testing, physical
examinations, MDCTA (to assess progression of low-attenuation plaque volume), and safety evaluation. Safety will also be assessed at 3 months
for all patients and at 15 months for patients continuing for a total of 18 months of treatment. *If a statistician and the Data Safety and
Monitoring Board find that efficacy is not achieved at 9 months, patients will be followed for an additional 9 months to assess progression of
low-attenuation plaque volume by MDCTA. If a P value of ≤0.006 is achieved at 9 months, then the study will terminate because the efficacy
boundary will have been achieved. Abbreviations: BP, blood pressure; EVAPORATE, Effect of Vascepa on Improving Coronary Atherosclerosis in
People With High Triglycerides Taking Statin Therapy study; MDCTA, multi-detector computed tomography angiography
TABLE 1 EVAPORATE key inclusion and exclusion criteria
Inclusion Criteria Exclusion Criteria
Age 30–85 y Use of medications or dietary
supplements that may alter plasma
lipids
Elevated TG (200–499 mg/dL) BMI >40 kg/m2
LDL-C ≥40 and ≤115 mg/dL
on statin therapy
History of known MI, stroke, life-
threatening arrhythmia, or HF
Stable diet and exercise Pregnancy
Stable treatment with a
statin  ezetimibe
Known genetic mutations/
polymorphisms that affect plasma
lipids
Patients with narrowing of
≥20% in 1 coronary artery
by invasive angiography or
MDCTA
Written informed consent
Abbreviations: BMI, body mass index; EVAPORATE, Effect of Vascepa on
Improving Coronary Atherosclerosis in People With High Triglycerides
Taking Statin Therapy study; HF, heart failure; LDL-C, low-density lipo-
protein cholesterol; MDCTA, multi-detector computed tomography angi-
ography; MI, myocardial infarction; TG, triglycerides.
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volume decrease was seen at 6 months in the EPA + statin group
from 18.5 mm3 (baseline) to 15.0 mm3 (follow-up), vs an increase
from 17.8 mm3 (baseline) to 19.3 mm3 (follow-up) in those treated
with statin alone (P = 0.013 for difference between EPA vs con-
trol).20 In the Combination Therapy of Eicosapentaenoic Acid and
Pitavastatin for Coronary Plaque Regression Evaluated by Integrated
Backscatter Intravascular Ultrasonography (CHERRY) study, plaque
regression was defined as >14.6% decrease based on percent change
in plaque volume observed in a cohort of acute coronary syndrome
(ACS) patients undergoing percutaneous intervention and sequential
IVUS evaluation over 6 months.21 The prevalence of total atheroma
volume regression was significantly higher in the EPA + pitavastatin
group vs the pitavastatin-alone group (81% vs 61%; P < 0.002 for dif-
ference).22 In the EPA arms in these 2 studies, plaque lipid volume
decreased by approximately 11% to 19%. In an MDCTA study of EPA
vs ezetimibe, there was a decrease in what was believed to be the
percent lipid or fatty plaque volume from 29.2 to 25.1 (−14%, calcu-
lated by percent change from baseline to follow-up in plaque volume
ranging from −50 to 50 HU for EPA-treated groups); the same range
of −50 to 50 HU will be used in the EVAPORATE study to represent
low-attenuation plaque volume (for additional details see Supporting
Information, Appendix, in the online version of this article).
Assuming an average of 1.7 measurable plaques per patient, with
intrapatient plaque correlation of 0.24,23 70 patients would provide
power of 0.80 and a 1-sided type 1 error of 0.05 to detect an 8% dif-
ference in plaque volume between the active and placebo groups.
The primary analysis will utilize intent-to-treat principles, with
study subjects analyzed by assigned treatment group regardless of
study drug adherence. Changes from baseline will be calculated with
95% confidence intervals. Statistical tests for outcomes will report 1-
sided P values (α: <0.048).
An interim analysis will be conducted at 9 months using the Lan-
DeMets version of the O'Brien-Fleming group sequential boundaries
for a 2-look sequential design (1 interim at 9 months + final analysis).
For the interim analysis, the statistical power to test the primary
study endpoint is 80% based on a sample size of 70 patients random-
ized in a 1:1 allocation ratio and an overall experimental type 1 error
equal to 0.05 using a 1-sided hypothesis test. If a P value of ≤0.006
is achieved at 9 months, then the study will terminate because the
efficacy boundary will have been achieved.
A sensitivity analysis will be performed on the group of patients
adhering to interventions for >80% of the duration of the study.
Baseline analysis and comparison between treatment arms will
include demographics, coronary risk factors, atherosclerotic CV dis-
ease risk factors, laboratory tests, coronary calcium, and coronary pla-
que volume/composition.
Baseline characteristics will be presented as mean and SD or
median and interquartile range. Differences in baseline characteristics
between groups will use analysis of variance (ANOVA) for normally
distributed continuous traits and the χ2 or Fisher exact test for cate-
gorical variables. For normally distributed continuous outcomes,
including percent change in low-attenuation plaque, mean percent
group differences will be estimated using linear mixed models with
baseline value, time, and treatment group as fixed effects. Least
squares means will be estimated from the models. Models evaluating
per-patient outcomes will include fixed effects. Natural log-
transformations will be used for variables with log-normal distribu-
tions. For the analyses of the primary and secondary efficacy vari-
ables, the statistical modeling assumptions will be examined. If
significant departures from normality (P < 0.01 for the Shapiro–Wilk
test) and/or homogeneity of variance are observed, the nonparamet-
ric analysis approach will be considered. When parametric and non-
parametric results do not corroborate each other, the results from
the nonparametric analysis will be used. Otherwise, the parametric
analysis will be reported.
2.5 | Compliance
After randomization, participants will be evaluated at 3, 9, and
12 months, and, if needed, at 15 months (by phone) and 18 months
to assess compliance with study medication. Patients will return with
pill bottles, and counts of remaining medications will be made at each
visit.
2.6 | Ethical considerations and study organization
The study is being conducted in compliance with institutional review
boards/institutional ethics committees, the principles of the Declara-
tion of Helsinki, the International Conference on Harmonisation
Good Clinical Practice guidelines, and relevant local laws and regula-
tions. All patients will provide written informed consent. The Data
Safety Monitoring Board will meet at 6-month intervals to monitor
study progress, safety, and efficacy. Study organization and leader-
ship details are available in Supporting Information, Appendix, in the
online version of this article.
2.7 | Study status
At the time of writing of this manuscript, the study was approxi-
mately 50% enrolled with an estimated study completion in the third
quarter of 2019.
TABLE 2 EVAPORATE study endpoints
Primary endpoint
Change in low-attenuation plaque volume as measured by MDCTA
and defined as −50 to 50 HU
Secondary endpoints
Incident plaque rates; quantitative changes in different plaque types
and morphology
Changes in markers of inflammation including Lp-PLA2 and hsCRP
Changes in lipids and lipoproteins including standard lipid panel,
lipoproteins, remnants, Apo-A1/remnant ratio, EPA, AA, and
EPA/AA ratio
Relationship between changes in the above with noncalcified
coronary plaque burden and/or plaque-vulnerability features
Abbreviations: AA, arachidonic acid; Apo-A1, apolipoprotein A1; EPA,
eicosapentaenoic acid; EVAPORATE, Effect of Vascepa on Improving Cor-
onary Atherosclerosis in People With High Triglycerides Taking Statin
Therapy study; hsCRP, high-sensitivity C-reactive protein; HU, Hounsfield
units; Lp-PLA2, lipoprotein-associated phospholipase A2; MDCTA, multi-
detector computed tomography angiography.
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3 | DISCUSSION
Multiple lines of evidence support a strong rationale for the biologic
plausibility of EPA as an antiatherosclerotic agent capable of improv-
ing CV outcomes and reducing residual risk on top of statin therapy
by directly affecting atherosclerotic plaque. However, many of these
supporting studies were in Japanese populations without elevated
TG levels. The EVAPORATE study, which uses medical imaging to fol-
low atherosclerosis, is specifically designed to evaluate the effects of
high-purity prescription EPA (icosapent ethyl) 4 g/d on atheroscle-
rotic plaque using state-of-the-art MDCTA imaging in a North Ameri-
can population of statin-treated patients with elevated TG levels
(200–499 mg/dL).
The present trial was designed using a number of markers that
have never been studied in the context of low-attenuation plaque fol-
lowing treatment with EPA in a Western population. These include
serum EPA levels and the EPA/arachidonic acid (AA) ratio, both of
which have been shown to beneficially affect plaque and CV events
in a Japanese population.24 However, a meta-analysis of large ran-
domized controlled studies suggests that blood levels of AA may have
an inverse relationship with CV outcomes.25 The meta-analysis did
not evaluate the relationship between the EPA/AA ratio and CV out-
comes; therefore, the significance of these findings on the present
study is not known. Additionally, studies of the apolipoprotein
A1/remnant ratio have been limited,26,27 and the relationship
between this ratio and low-attenuation plaque has not yet been pub-
lished to our knowledge.
Prior imaging studies of the effects of EPA on atherosclerotic
plaque using angiography, IVUS, IB-IVUS, carotid ultrasound, and
optical coherence tomography have begun to elucidate the role of
EPA intervention in atherosclerotic disease8; data regarding MDCTA
are presently limited to congress abstracts and non-Western popula-
tions.28,29 In a study of 43 Japanese patients with 51 lesions and sus-
pected coronary artery disease, patients were treated with either
EPA or ezetimibe; MDCTA evaluations were conducted at baseline
and at 1 year.28 EPA-treated patients experienced significant reduc-
tions in soft-plaque volume compared with ezetimibe-treated
patients (−50 to 0 HU component; P = 0.036 for difference between
EPA and ezetimibe).28 Significant reductions in plaque area
(P = 0.017) and lumen area (P = 0.004) were also observed in the
EPA-treated group compared with the ezetimibe group.28 Addition-
ally, the incidence of major coronary events was significantly lower
(P = 0.03) in the EPA group (9.5%) compared with the ezetimibe
group (36.4%).28 The data suggest that EPA played a beneficial role in
coronary plaque stabilization. Another Japanese study assessed pla-
que progression in ACS patients treated with EPA (n = 33) or EPA +
docosahexaenoic acid (DHA; n = 29) and in untreated control
patients (n = 20) via serial CCTA at baseline and at 1 year.29 All
patients were on statin therapy after the baseline assessment. After
1 year, there was a significant difference in the progression of plaque
between the 3 groups (P = 0.0061), with progression observed in 3%,
14%, and 35% of patients in the EPA, EPA + DHA, and control
groups, respectively.29 Another study worth noting is the recent
HEARTS study of statin-treated patients with stable coronary artery
disease and well-controlled LDL-C, which demonstrated that high-
dose EPA + DHA prevented the progression of fibrous coronary pla-
que volume over 30 months compared with statin alone using
CCTA.30
The use of MDCTA allows for the noninvasive examination of
plaque composition, severity of vessel stenosis, plaque volume, and
extent of remodeling.31 MDCTA also can measure plaque burden.32
The technique is now used in clinical investigations evaluating a range
of therapies including testosterone, garlic, statins, hormone replace-
ment, anti-inflammatory agents, and antidiabetes agents. MDCTA
yields high reproducibility of measurements33 and allows for evalua-
tion of the entire coronary tree. Although MDCTA is a relatively new
technique, it has been shown to have high reproducibility, with <1%
variability for measuring noncalcified and calcified plaque volume and
<15% variability for total plaque.34 MDCTA also has been shown to
correlate with IVUS in measuring lipid plaque volume.35,36 In addition,
a study by Nakanishi et al37 showed for the first time that nonob-
structive low-attenuation plaques, visualized on MDCT, were associ-
ated with ACS events during 3 years of follow-up in patients with
hypertension and were a more powerful predictor than traditional
risk factors, including Framingham risk score, carotid intima-media
thickness, and left ventricular mass index.
Cardiovascular outcomes in North American patients treated
with high-dose icosapent ethyl (4 g/d) are being investigated in the
Reduction of Cardiovascular Events With Icosapent Ethyl–
Intervention Trial (REDUCE-IT; NCT01492361).38 REDUCE-IT is a
phase 3b, international, randomized, double-blind, placebo-controlled
study that is evaluating whether treatment with icosapent ethyl
reduces ischemic events in a statin-treated patient population similar
to that of the EVAPORATE study (TG levels ≥150 mg/dL and
<500 mg/dL, LDL-C levels >40 mg/dL and ≤100 mg/dL, and at ele-
vated CV risk). Of note, whereas EVAPORATE will utilize medical
imaging data, REDUCE-IT focuses on clinical CV event outcomes.38
REDUCE-IT has randomized approximately 8000 patients and is near-
ing completion, with final results anticipated to be reported during
2018.38 The populations studied in EVAPORATE and REDUCE-IT
represent a relatively large population: based on approximations from
large CV outcomes trials including or limited to patients with type
2 diabetes mellitus, roughly 25% to 40% of patients had TG levels
≥150 mg/dL and LDL-C levels <100 mg/dL, and roughly 15% to 20%
of patients had TG levels ≥200 mg/dL and LDL-C levels <100 mg/
dL.39–43 Another study of interest is the ongoing global Statin Resid-
ual Risk Reduction with Epanova in High CV Risk Patients with
Hypertriglyceridemia trial (STRENGTH; NCT02104817), which is
evaluating the effects of a DHA + EPA combination product (omega-
3 carboxylic acids; high dose) on CV outcomes in patients with TG
levels ≥180 mg/dL and <500 mg/dL and LDL-C levels <100 mg/dL.
As STRENGTH will be evaluating the combination of EPA and DHA,
the findings from EVAPORATE may not directly or indirectly inform
the findings.
The findings of the EVAPORATE study will add to our under-
standing of the role of EPA intervention in the treatment of athero-
sclerotic plaque in that the study will assess statin-treated patients
using MDCTA and high-purity EPA (icosapent ethyl) at a dose known
to raise plasma EPA to levels similar to those observed in JELIS,
which demonstrated significant reduction in risk of major coronary
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events in Japanese patients. EVAPORATE may also contribute to the
understanding of the pathophysiologic underpinnings of the results
of the EPA-only REDUCE-IT study.
4 | CONCLUSION
EVAPORATE will be the first study using MDCTA to evaluate the
effects of icosapent ethyl on atherosclerotic plaque as an adjunct to
statin therapy in a North American population with persistent high
TG levels, and it will assess whether these effects correlate with lipid
changes and inflammatory markers. The clinical implications of icosa-
pent ethyl 4 g/d as an adjunct to statin therapy on CV endpoints are
also being evaluated in the large CV outcomes study REDUCE-IT.
EVAPORATE will provide important mechanistic data that may have
relevance to the REDUCE-IT results.
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